Literature DB >> 15152989

Stereoselective synthesis of a potent thrombin inhibitor by a novel P2-P3 lactone ring opening.

Todd D Nelson1, Carl R LeBlond, Doug E Frantz, Louis Matty, Jeffrey V Mitten, Damian G Weaver, Jeffrey C Moore, Jaehon M Kim, Russell Boyd, Pei-Yi Kim, Kodzo Gbewonyo, Mark Brower, Michael Sturr, Kathleen McLaughlin, Daniel R McMasters, Michael H Kress, James M McNamara, Ulf H Dolling.   

Abstract

The concise synthesis of a potent thrombin inhibitor was accomplished by a mild lactone aminolysis between an orthogonally protected bis-benzylic amine and a diastereomerically pure lactone. The lactone was synthesized by the condensation of l-proline methyl ester with an enantiomerically pure hydroxy acid, which in turn was synthesized by a highly stereoselective (>500:1 er) and productive (100,000:1, S/C) enzymatic reduction of an alpha-ketoester. In addition, a second route to the enantiomerically pure lactone was accomplished by a diastereoselective ketoamide reduction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15152989     DOI: 10.1021/jo035794p

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  3 in total

1.  Improved Stability of Proline-Derived Direct Thrombin Inhibitors through Hydroxyl to Heterocycle Replacement.

Authors:  Harry R Chobanian; Barbara Pio; Yan Guo; Hong Shen; Mark A Huffman; Maria Madeira; Gino Salituro; Jenna L Terebetski; James Ormes; Nina Jochnowitz; Lizbeth Hoos; Yuchen Zhou; Dale Lewis; Brian Hawes; Lyndon Mitnaul; Kim O'Neill; Kenneth Ellsworth; Liangsu Wang; Tesfaye Biftu; Joseph L Duffy
Journal:  ACS Med Chem Lett       Date:  2015-03-13       Impact factor: 4.345

Review 2.  Diketomorpholines: Synthetic Accessibility and Utilization.

Authors:  Lan Phuong Vu; Michael Gütschow
Journal:  ACS Omega       Date:  2021-12-22

3.  Biocatalytic synthesis of chiral alcohols and amino acids for development of pharmaceuticals.

Authors:  Ramesh N Patel
Journal:  Biomolecules       Date:  2013-10-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.